The global telmisartan market size reached US$ 3.7 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 4.8 Billion by 2032, exhibiting a growth rate (CAGR) of 2.93% during 2023-2032.
Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.
Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.
Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.
Telmisartan Market Trends:
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments.Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global telmisartan market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and distribution channel.Breakup by Indication:
- Hypertension
- Cardiovascular Risk Reduction
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.Key Questions Answered in This Report:
- How has the global telmisartan market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global telmisartan market?
- What are the key regional markets?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global telmisartan market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface3 Executive Summary10 Value Chain Analysis12 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Telmisartan Market
6 Market Breakup by Indication
7 Market Breakup by Distribution Channel
8 Market Breakup by Region
9 SWOT Analysis
11 Porters Five Forces Analysis
13 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Aurobindo Pharma USA
- Boehringer Ingelheim International GmbH
- Cipla Limited
- Hikma Pharmaceuticals plc
- Jubilant Cadista Pharmaceutical
- Sanofi S.A.
- Solco Healthcare (Prinston Pharmaceutical Inc.)
- Torrent Pharmaceuticals Ltd.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 3.7 Billion |
| Forecasted Market Value ( USD | $ 4.8 Billion |
| Compound Annual Growth Rate | 2.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
